Nalaganje...
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions
Since the year 2000, tremendous progress has been made in the understanding of castration-resistant prostate cancer (crpc), a disease state now recognized to retain androgen receptor (ar)—dependency in most cases. That understanding led to the rational design of novel therapeutic agents targeting ho...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Multimed Inc.
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3553559/ https://ncbi.nlm.nih.gov/pubmed/23355790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.19.1281 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|